 Mind Bloom is a mental health and well-being company that delivers guided psychedelic therapy in a supportive environment. The company opened its first location in New York City in March with the pandemic crisis that timing could not have been better. 18 months ago, I became a ketamine patient in a clinical setting and saw that here's an opportunity to take this profound transformational medicine and help bring it to more people and increase access to help people who need it most to get the care that they need. And how are you reacting to the current COVID crisis? Because we've been hearing that some doctors don't wanna see patients in person right now. And with this particular situation, because this virus is so frightening, I would think that you're very patient to the ones that really need treatments the most right now that maybe their anxiety levels have skyrocketed or maybe if they weren't even an existing patient that if they weren't one before, they are one now. How are you guys responding? You nailed it Deb. We used to say that mental health care is the number one public health crisis in the United States and that's no longer the case. Coronavirus is without a doubt the number one public health crisis in the United States or in a state of emergency. The way that we've responded, I'm really proud of our clinicians for really feeling the call to service during this time, is we had already begun piloting virtual and remote sessions to help increase access to treatment. So essentially, like, telepsychedelics. And we had already done through the platform a couple hundred remote sessions for people who had started their journey in MindBloom's Nomad Center. And so now in response to Coronavirus, we are really excited to announce that our clinicians are treating 100% virtually. So remote enabled and guided psychedelic therapy sessions with God Academy therapy so that people can stay home and get the treatment that they need for their anxiety and depression without having to come in to keep both our clinicians and clients safe in these tough times. And beyond the inpatient experience, MindBloom also has special software that you've created around the treatment process. Can you dig into that a little bit better? Is that like follow-up software or how does this software relate to the treatment? Yeah, absolutely. So from day one, we set out to become a technology company helping use technology to increase access to people and to help our clinicians improve outcomes to help people really get the most out of these treatments. So you can kind of think of it as a tele therapy meets a headspace platform designed specifically for psychedelic therapy where clients are able to do video consults and video therapy to prepare and integrate their experiences with trained psychiatric clinicians and therapists and the platform also helps people with guided psychedelic therapy contents including like audio states with guided meditations and music for their sessions and journaling prompts and other content to help them really maximize the experience. One of the things that I know you're planning to do is expand. So right now you mentioned you're in Manhattan and you've got plans to go into other cities. What are those other cities and what are the goals here? We're already going to expand into states that have in the state of emergency dropped their in-state licensure requirements for physicians and clinicians to need a license in that state to practice. So that's an effort to respond to the coronavirus crisis by helping to increase access to behavioral health and mental health care treatments. And then we're going to continue to expand across the country over the next year or two with both our clinic-based and remote-based approaches. And how are you funded? Because you are a new company, expansion is not cheap and I was just curious, are you self-funded? Have you done a raise? What has gotten you to this point? They were a venture-backed health care technology company. We closed our first round of funding in the summer of last year to begin treating our first cohort of clients through the platform and bringing clinicians on to do that treatment. And so we've raised funding from some of the biggest investors in healthcare technology and psychedelic medicine. So some of the same people who've funded and backed ZocDoc and HIMS and Oscar and Tumpas Pathways. Mind Bloom is currently focused on ketamine but as more psychedelic compounds are legalized that will expand. We don't think of Mind Bloom as either a ketamine therapy company nor even a psychedelic medicine company but as a next generation mental health and well-being platform who are helping to increase access to the most effective science-backed mental health and well-being treatments available. Today, based on research, based on my experience, based on the experience of our medical director, Dr. Casey Palios who's a principal investigator on the MDMA clinical trials and was like an early pioneer in ketamine therapy research and practice. We think the ketamine is the most effective science-backed treatment that is not readily or widely available to people. So that's our focus today but we are super excited based on everything I just mentioned plus the research for MDMA assisted therapy which is in phase three clinical trials, psilocybin assisted therapy which is in phase two clinical trials both breakthrough therapies designation by the FDA as well as other non-s psychedelic medicine treatments that we think are gonna be really powerful to help people with anxiety depression and other conditions that we begin helping people with. Well, that's fantastic. Thank you so much for joining us and good luck with that. And really, I think it's super that you're out there helping people, helping them through this crisis and helping them so that they can be functioning adults. That's Dylan Bynum with Mind Bloom and I'm Deborah Portchart with the Green Marker Report.